Sanofi (SNYNF) News Headlines

▮ More

Date

Headline

5/7/2019 9:21:59 AM Regeneron & Sanofi: Dupixent Approved For Severe Asthma Indication In EU

5/7/2019 9:06:57 AM Regeneron And Sanofi Announce That EC Approve New Indication For Dupixent In Asthma

4/29/2019 12:52:49 AM Sanofi: FDA Approves Praluent To Prevent Heart Attack, Stroke, Unstable Angina

4/26/2019 3:15:22 AM Biotech Stocks Facing FDA Decision In May 2019

4/26/2019 2:01:30 AM Sanofi Q1 Profit Rises; Backs 2019 Business EPS Outlook - Quick Facts

4/26/2019 1:42:59 AM Sanofi Q1 Business EPS EUR 1.42, Up 10.9% Or 9.4% At CER

4/10/2019 5:03:27 AM Sanofi Provides Unprecedented Access To Its Insulins For One Set Monthly Price

4/8/2019 1:03:11 AM Alnylam And Sanofi Conclude Research And Option Phase Of 2014 RNAi Therapeutics Collaboration

4/4/2019 6:58:41 AM Denali Therapeutics - On The Move

3/26/2019 7:16:18 AM Biotech Stocks Facing FDA Decision In April

3/23/2019 12:41:16 AM Sanofi: FDA Issues CRL For Zynquista

3/8/2019 1:06:22 AM Regeneron And Sanofi Say FDA Accept For Priority Review SBLA For Dupixent

3/8/2019 1:02:12 AM Regeneron And Sanofi : FDA Accept For Priority Review SBLA For Dupixent

3/1/2019 8:43:22 AM Regeneron Says CHMP Recommends Approval Of Dupixent For Asthma Indication

3/1/2019 8:37:48 AM Regeneron And Sanofi Say CHMP Recommends Approval Of Dupixent For Asthma Indication

2/26/2019 10:51:26 PM Biotech Stocks Facing FDA Decision In March

2/25/2019 5:27:36 PM Regeneron, Sanofi Says Disagree With Verdict Upholding Three Of Five Amgen U.S. Patent Claims On PCSK9 Antibodies

2/25/2019 5:13:40 PM Amgen: Delaware Jury Upholds Validity Of Two Patents Related To PCSK9 Antibodies

2/12/2019 1:17:45 AM Sanofi Appoints Ameet Nathwani As Chief Digital Officer

2/11/2019 7:37:06 AM Sanofi, Regeneron Offer Praluent At 60% Reduced U.S. List Price - Quick Facts